Sign in

    ICAD Inc (ICAD)

    Q1 2024 Earnings Summary

    Reported on Jan 30, 2025 (Before Market Open)
    Pre-Earnings Price$1.58Last close (May 14, 2024)
    Post-Earnings Price$1.57Open (May 15, 2024)
    Price Change
    $-0.01(-0.63%)

    What went well

    • iCAD is successfully transitioning to a recurring revenue model, with a significant increase in subscription deals; in Q1 2024, they completed 16 subscription deals, reflecting the company's focus on maximizing annual recurring revenue. The sales team is incentivized to push for subscription and cloud-based deals, which could lead to more stable and predictable revenue growth.
    • Strong revenue growth in Q1 2024 driven by key deals, including a significant deal with Raleigh Radiology worth over $300,000, and expansion into additional sites totaling close to $500,000 in revenue for the quarter. This indicates effective sales efforts and the ability to secure large contracts, contributing to a quarterly revenue increase of 14% over the prior year.
    • Launch and commercial availability of ProFound Cloud, iCAD's cloud-based SaaS platform, represents a significant growth opportunity. The platform is now commercially available, and the sales team has already secured their first cloud deal in Q2 2024, suggesting early traction and potential for new recurring revenue streams.

    What went wrong

    • Seasonality still affects ICAD's business, with customers tending to delay purchases until later in the year to see if they have budget remaining. This delay can lead to uneven revenue distribution and potential forecasting challenges.
    • Customers may wait to get better deals, knowing that by waiting longer, especially towards the end of the year, they may receive better discounts. This expectation can pressure ICAD's pricing power and margins due to the need to offer discounts to secure sales.
    • Customers can afford to wait in their decision-making process, indicating that ICAD's products may not be seen as immediately critical, which could impact sales velocity and the ability to close deals promptly.

    Q&A Summary

    1. Revenue Growth Drivers
      Q: What caused revenue growth this quarter despite typical seasonality?
      A: The company experienced a significant revenue increase this quarter due to a couple of key factors. Notably, a deal with Rally Radiology, which had been in the works for over a year, contributed over $300,000 in revenue. Additionally, expansion into another 4 or 5 sites added close to $500,000 in total revenue for the quarter. These factors offset the usual seasonal decline and caused the revenue bump.

    2. FDA Approval Timeline
      Q: Are key products still on track for late '24 FDA approvals?
      A: The timeline for FDA approvals may extend, but the best-case scenario is still the end of the calendar year. For the 4.0 detection algorithm, new cybersecurity requirements are causing delays, as this is the first time the FDA is rolling them out. Similarly, for Heart Health, while the company is working to firm up the necessary data, having a predicate device on the market is helping to address FDA questions.

    3. Shift to Recurring Revenue
      Q: Will the increase in subscription deals continue?
      A: The company saw an increase to 16 subscription deals this quarter. While there will be ebbs and flows, the team is incentivized to push for more recurring revenue through subscriptions and the new cloud release in Q1. The organization aims to maximize Annual Recurring Revenue (ARR) and is focusing on both subscription and cloud models.

    4. ProFound Cloud Sales
      Q: Is ProFound Cloud ready and generating sales?
      A: Yes, ProFound Cloud is commercially available, and the sales team is actively selling it. The first deal has already occurred in the second quarter, and more details will be shared in the next earnings call.

    5. Sales Team Stability
      Q: Are more sales team additions expected?
      A: The sales team is considered stable for the rest of the calendar year. While there might be role adjustments to optimize performance in winning new business versus expanding existing accounts, no significant changes in team quantity are anticipated.

    6. Lead Generation and Commercial Model
      Q: What changes have been made to lead generation and the commercial model?
      A: The company implemented a structured lead generation process, leveraging platforms like LinkedIn and optimizing trade show participation. They have restructured the sales team into segmented roles focused on new business and retention, revamped pricing models with the introduction of cloud solutions, and are reporting ARR based on a subscription pricing model.

    7. Seasonality in Revenue
      Q: Does seasonality still affect revenue?
      A: Yes, seasonality still applies due to customers' budget cycles and purchasing behaviors. Many customers are on a calendar year budget and may wait until year-end to make purchasing decisions, sometimes to obtain better deals. These factors contribute to predictable seasonal patterns in revenue.

    Related Publications